Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMCOpen access

Macrophage migration inhibitory factor from nematode parasite as a novel approach to combat obesity and its metabolic complications

Park MK., Cho M., Yu HS.

Animal Study on Chronic Inflammation, Immune Modulation, published in Front Immunol (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Front Immunol (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41727486
PMCID
PMC12916604
DOI
10.3389/fimmu.2026.1742993

Abstract (original English)

Objective Obesity is a complex chronic disease characterized by excessive fat accumulation, dysregulation of energy homeostasis, and associated mild inflammation, significantly increasing the risk of metabolic diseases, cardiovascular diseases, and other chronic diseases. Addressing this requires innovative approaches targeting the underlying mechanisms. This study investigates the therapeutic effects of Anisakis simplex- derived macrophage migration inhibitory factor (1) on adipogenesis, lipid metabolism, and inflammation in high-fat diet (2)-induced obesity. Methods We evaluated the effects of rAs-MIF on adipocyte differentiation, lipid droplet formation, and expression of adipogenic and inflammatory genes in 3T3-L1 cells. In addition, we investigated the effects of orally administered rAs-MIF on lipid accumulation, glucose metabolism, serum biochemical markers, and immune regulation in mice fed a 45% high-fat diet. Results rAs-MIF dose-dependently reduced lipid droplet size and triglyceride accumulation, inhibited adipogenesis and inflammatory gene expression, and upregulated adiponectin levels in 3T3-L1 cells. In HFD-fed mice, rAs-MIF decreased body weight gain, fat mass, and serum lipid levels, enhanced glucose tolerance, and activated interscapular brown adipose tissue while suppressing epididymal white adipose tissue lipid synthesis. Moreover, it modulated the immune bal

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
3T3-L1 CellsAdipocytesMacrophagesAnimalsMice, Inbred C57BLMiceObesityMacrophage Migration-Inhibitory FactorsMaleAdipogenesis

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research